Encompass Health (EHC) to Release Quarterly Earnings on Thursday

Encompass Health (NYSE:EHC) is anticipated to release its Q1 2025 earnings data after the market closes on Thursday, April 24th. Analysts expect Encompass Health to post earnings of $1.19 per share and revenue of $1.43 billion for the quarter. Encompass Health has set its FY 2025 guidance at 4.670-4.960 EPS.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. On average, analysts expect Encompass Health to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Encompass Health Trading Up 2.9 %

Shares of NYSE EHC opened at $98.95 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health has a 12 month low of $80.49 and a 12 month high of $104.55. The company has a market cap of $9.96 billion, a price-to-earnings ratio of 22.19, a P/E/G ratio of 2.31 and a beta of 0.87. The business has a fifty day simple moving average of $99.85 and a 200-day simple moving average of $98.31.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were issued a $0.17 dividend. The ex-dividend date was Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.69%. Encompass Health’s payout ratio is currently 15.25%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on EHC shares. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. StockNews.com downgraded Encompass Health from a “buy” rating to a “hold” rating in a report on Wednesday, April 16th. Barclays raised their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. KeyCorp upped their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $107.67.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.